SCHEMBL10003106

SCHEMBL10003106

CCc1cc2c(nc1-c1ccccc1F)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA2 P42262 1/20 0.37
▸ GRIA4 P48058 1/20 0.37
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35
▸ MAPT P10636 3/20 0.34
▸ TP53 P04637 2/20 0.34
▸ CTSA P10619 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ DHODH Q02127 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA2B P29275 1/20 0.32
▸ ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003729 0.90 ALDH1A1 (0.42) MAPTTP53MEN1KMT2ATSHR
SCHEMBL10003803 0.89 MAPT (0.35) MAPTMEN1KMT2ATSHRKDM4E
SCHEMBL10003507 0.87 GRIA2 (0.39) GRIA2GRIA4HCRTR1HCRTR2MAPT
SCHEMBL10003857 0.87 MCL1 (0.36) MAPTTP53MEN1KMT2AKDM4E
SCHEMBL10003551 0.84 GRIA2 (0.37) GRIA2GRIA4KDM4EALDH1A1HPGD
SCHEMBL10003432 0.83 PDE5A (0.37) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL10003403 0.80 ERCC1 (0.35) MAPTTP53MEN1KMT2AKDM4E
SCHEMBL10004046 0.80 SMO (0.45) TP53MEN1KMT2AKDM4EALDH1A1
SCHEMBL10003241 0.80 PPARD (0.38) DHODH
SCHEMBL10002819 0.79 ALDH1A1 (0.39) MAPTMEN1KMT2ATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GRIA2 3298/4885GRIA4 2962/4885HCRTR1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback